BRD4 and uveal melanoma: Preclinical research has demonstrated inhibition of gene expression and antitumor effects with BET inhibitors in uveal melanoma [14] and adenoid cystic carcinoma cell lines [30], with preliminary dose-dependent efficacy found in uveal melanoma in humans [31] The antitumor effect of a BET inhibitor in uveal melanoma [14] or adenoid cystic carcinoma [30] has been postulated to occur via cell cycle arrest due to inhibition of BRD4.